24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
AHA News: Could Fish Oil Fight Inflammation?One Boy's Battle Back From Mysterious Polio-Like IllnessHealth Tip: Advice on Home Wound CareOver 40% of Antibiotics Could Be 'Inappropriately' PrescribedRural Seniors Hurt by Lack of Medical SpecialistsHealth Tip: Understanding Muscle SpasmsBlack Patients May Not Gain Heart Benefit From Low-Dose AspirinIs Pot Use a Heart Risk After Surgery?E. Coli Outbreak Spurs Packaged Salad WarningHealth Tip: Should I Get a Cholesterol Test?Are Superbugs Making Themselves at Home in Your Makeup Bag?Sometimes, Aspirin May Be Enough to Ease MigrainesDangers of 'Superbug' Germs Greater Than BelievedAdditives to E-Cigarettes May Be Upping Health DangersMany Kids Traveling Overseas Aren't Vaccinated Against MeaslesVirtual Doc Visits Suffice for Many With Neurological DisordersBPA Levels in Humans Are Underestimated: StudyCleaner Air Quickly Brings Big Health Benefits, Study FindsAll 50 States Now Reporting Cases of Severe Vaping-Linked Lung Injury3 Drugs for Severe Epileptic Seizures Are Equally Effective: StudyStudy Casts Doubt on Use of Common Heart Failure Drugs'Mobile Stroke Units' Help Rush Treatment to PatientsDistracted by Their Smartphones, Pedestrians Are Landing in the ERVaping May Have Triggered Lung Illness Typically Only Seen in MetalworkersMore Than 100 E. Coli Illnesses Now Linked to Romaine LettuceLow-Dose Aspirin Might Cut Cancer Risk, Especially for Overweight PeopleEspecially in the Young, Cholesterol Is No Friend to the HeartAre E-Scooters a Quick Ticket to the ER?Uncontrolled Asthma a Danger to Pregnant Women, BabiesHealth Tip: Common Causes of Knee PainSome Cities' Smog Can Ruin Your VacationParkinson's Treatment Has Unexpected Side EffectHeart Attack at 44 Helped Her Realize Diabetes' DangersCleaner Teeth, Healthier Heart?Obesity Might Weaken Some Drugs' Effectiveness Against AFibHow to Prevent Holiday HeadachesAir Pollution May Up Glaucoma RiskHealth Tip: Causes of Stomach UlcersHealth Tip: Treating ShinglesLeg Pain Could Spell Peripheral Artery Disease for SomeEven in Small Doses, Air Pollution Harms Older AmericansDon't Let Allergies Spoil Your HolidaysGot Chronic Heartburn? Easy Does It During the Thanksgiving FeastAHA News: Flu Prevention Strategies Beyond Getting a Shot and Washing Your HandsUltrasound Treatment Might Ease Parkinson's TremorsPopular Heartburn Drugs May Up Odds of Stomach BugGunshot Wounds Have Long-Term Health Consequences: StudyU.S. Poison Centers Field More Calls About Psychoactive Substances: StudyMore E. coli Illnesses Linked to Tainted Romaine LettuceFDA Approves First System to Insert Ear Tubes Under Local Anesthesia
Questions and AnswersLinks
Related Topics

Diabetes

Drug Trio Could Give Patients With Cystic Fibrosis a New Option

HealthDay News
by -- Robert Preidt
Updated: Nov 1st 2019

new article illustration

FRIDAY, Nov. 1, 2019 (HealthDay News) -- A three-drug combo that significantly improves lung function in cystic fibrosis patients could benefit 90% of people with the life-threatening disease, a new study suggests.

It included patients with a single copy of the most common genetic mutation for the disease.

Results of the international phase 3 clinical trial led the U.S. Food and Drug Administration to approve the therapy last month. The findings were published Oct. 31 in the New England Journal of Medicine.

"This should be a major cause for celebration," Dr. Francis Collins, director of the U.S. National Institutes of Health, wrote in an editorial accompanying the new study.

Cystic fibrosis (CF) is a progressive genetic disease that causes thick mucus to build up in the lungs, digestive tract and other parts of the body, resulting in severe respiratory and digestive problems and other complications such as infections and diabetes.

"Although there are over a thousand different disease-causing mutations, nearly 90% of people with cystic fibrosis have at least one copy of the most common mutation, the Phe508del CFTR allele," said study corresponding author Dr. Raksha Jain. She's director of the Adult Cystic Fibrosis Center at University of Texas Southwestern Medical Center in Dallas.

About 80,000 people worldwide have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) protein, according to Jain. People inherit a gene from each parent that encodes the CFTR protein.

"This three-drug combination was highly effective in people with cystic fibrosis who inherited the Phe508del CFTR mutation, improving health outcomes and symptoms," Jain said in a university news release.

The study, conducted at 115 sites in 13 countries, included 403 patients with one mutated copy of the gene.

Patients were randomly selected to receive either the elexacaftor-tezacaftor-ivacaftor combo (Trikafta) or a placebo. The trial was co-sponsored by Vertex Pharmaceuticals, which makes the drug combo. Its list price is $311,500 a year.

Patients' lung function was assessed at four and 24 weeks. Compared to those in the placebo group, patients who took Trikafta had significantly improved lung function at both checkups.

Symptom flare-ups were 63% lower in the Trikafta group, and these patients also had better questionnaire scores on quality of life and respiratory symptoms than the placebo group, according to the study.

Excessive amounts of salt in sweat is a hallmark of cystic fibrosis. People in the Trikafta group had a lower concentration of salt in their sweat than those in the placebo group, which suggests that the therapy targets the disease's underlying cause, Jain said.

For his part, Collins said that enthusiasm over the study's results should be tempered by the knowledge that 10% of patients won't be helped by this therapy.

"We must not abandon the patients with cystic fibrosis who … will not have a response to these drugs," he wrote. "The 'best day ever' for all of us traveling down this long road together will be the day when the more than 70,000 persons with cystic fibrosis worldwide do not need to take drug therapy at all and there finally is a permanent cure for cystic fibrosis that works for everyone."

And 1% of the Trikafta group stopped taking the drugs due to adverse events, the study authors noted. Further research is needed to learn more about potential side effects, Jain said.

She was also involved in a study that assessed Trikafta on patients with one or two copies of the Phe508del CFTR allele. That study was recently published in The Lancet medical journal.

Jain is presenting results of both studies this week at the North American Cystic Fibrosis Conference, in Nashville, Tenn.

"The CF community is working hard to find highly effective therapies for people who are not eligible for this treatment because they don't have the appropriate gene mutation," she said.

More information

The American Lung Association has more on cystic fibrosis.